Literature DB >> 11323414

Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling.

G C Blobe1, W P Schiemann, M C Pepin, M Beauchemin, A Moustakas, H F Lodish, M D O'Connor-McCourt.   

Abstract

Transforming growth factor beta (TGF-beta) signals through three high affinity cell surface receptors, TGF-beta type I, type II, and type III receptors. The type III receptor, also known as betaglycan, binds to the type II receptor and is thought to act solely by "presenting" the TGF-beta ligand to the type II receptor. The short cytoplasmic domain of the type III receptor is thought to have no role in TGF-beta signaling because deletion of this domain has no effect on association with the type II receptor, or with the presentation role of the type III receptor. Here we demonstrate that the cytoplasmic domains of the type III and type II receptors interact specifically in a manner dependent on the kinase activity of the type II receptor and the ability of the type II receptor to autophosphorylate. This interaction results in the phosphorylation of the cytoplasmic domain of the type III receptor by the type II receptor. The type III receptor with the cytoplasmic domain deleted is able to bind TGF-beta, to bind the type II receptor, and to enhance TGF-beta binding to the type II receptor but is unable to enhance TGF-beta2 signaling, determining that the cytoplasmic domain is essential for some functions of the type III receptor. The type III receptor functions by selectively binding the autophosphorylated type II receptor via its cytoplasmic domain, thus promoting the preferential formation of a complex between the autophosphorylated type II receptor and the type I receptor and then dissociating from this active signaling complex. These studies, for the first time, elucidate important functional roles of the cytoplasmic domain of the type III receptor and demonstrate that these roles are essential for regulating TGF-beta signaling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323414     DOI: 10.1074/jbc.M100188200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

Review 1.  Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.

Authors:  Karthikeyan Mythreye; Gerard C Blobe
Journal:  Cell Signal       Date:  2009-05-08       Impact factor: 4.315

2.  TGF beta2-induced changes in LRP-1/T beta R-V and the impact on lysosomal A beta uptake and neurotoxicity.

Authors:  Pirooz Eslami; Ming F Johnson; Ellen Terzakaryan; Carolyn Chew; Marni E Harris-White
Journal:  Brain Res       Date:  2008-09-10       Impact factor: 3.252

3.  Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC.

Authors:  Todd A Townsend; Jamille Y Robinson; Tam How; Daniel M DeLaughter; Gerard C Blobe; Joey V Barnett
Journal:  Cell Signal       Date:  2011-09-14       Impact factor: 4.315

4.  Changes in expression of genes related to cell proliferation in human mesenchymal stem cells during in vitro culture in comparison with cancer cells.

Authors:  Rumi Sawada; Tomomi Ito; Toshie Tsuchiya
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

5.  Regulation of growth factor receptor degradation by ADP-ribosylation factor domain protein (ARD) 1.

Authors:  Victor Meza-Carmen; Gustavo Pacheco-Rodriguez; Gi Soo Kang; Jiro Kato; Chiara Donati; Chun-Yi Zhang; Alessandro Vichi; D Michael Payne; Souheil El-Chemaly; Mario Stylianou; Joel Moss; Martha Vaughan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-08       Impact factor: 11.205

Review 6.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

7.  Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.

Authors:  Erik H Knelson; Angela L Gaviglio; Alok K Tewari; Michael B Armstrong; Karthikeyan Mythreye; Gerard C Blobe
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

8.  The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Authors:  Jason D Lee; Nadine Hempel; Nam Y Lee; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

9.  Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.

Authors:  Nadine Hempel; Tam How; Simon J Cooper; Tyler R Green; Mei Dong; John A Copland; Christopher G Wood; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2008-02-24       Impact factor: 4.944

10.  A novel family of adhesion-like molecules that interacts with the NMDA receptor.

Authors:  Chang-Yu Wang; Kai Chang; Ronald S Petralia; Ya-Xian Wang; Gail K Seabold; Robert J Wenthold
Journal:  J Neurosci       Date:  2006-02-22       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.